Vykat XR Adverse Events Rise as Industry Payments Correlate with Inappropriate Prescribing

The STAT report details an open letter from patient advocates and clinicians citing spontaneous reports of severe outcomes with Vykat XR, an extended-release diazoxide choline approved for hyperphagia. Case reports involve patients with multiple comorbidities and polypharmacy, preventing direct causality attribution. Neurocrine maintains the drug’s benefit-risk profile remains favorable based on pivotal trial data showing reduced hunger scores.

A 2023 Cochrane systematic review of 58 studies found that gifts, payments, and sponsored education from pharmaceutical companies were associated with a 23% relative increase in prescribing volume and higher rates of guideline-discordant choices. Absolute increases varied by drug class but averaged 1.2 additional prescriptions per physician per month in observational cohorts. Conflict-of-interest policies restricting such interactions reduced these effects in policy evaluations.

Payments data from Open Payments reveal several high-volume Vykat XR prescribers received consulting fees exceeding $50,000 in the prior two years, a pattern observed across rare-disease launches where small patient populations amplify per-physician influence. This dynamic raises questions about whether rapid uptake outpaced post-marketing safety monitoring.

The FDA’s next step will likely involve an advisory committee review once cumulative reports exceed 150 events. Independent analyses using claims data are needed to compare adverse event rates between compensated and non-compensated prescribers.